Component
Serum PLP to pyridoxal ratio
Independently recorded entity or measured process. Linked claims specify compartment, assay and experimental scope.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Enzyme replacement was associated with lower serum PLP: PL ratios; CSF PL was higher in treated than untreated cases.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- experimental_model
- Over 100 hypophosphatasia cases, serum vitamers and available CSF; supplementation/enzyme-replacement subgroups.
- exposure
- Observational clinical sampling by subtype and treatment; no randomized B6 efficacy comparison.
- limitations
- Nonrandomized treatment comparisons; does not directly measure transport flux or establish neurological benefit.
- nutrient_topic
- Vitamin B6 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin B6
- organism
- Homo sapiens
- plain_language
- Restoring enzyme activity changed B6 handling markers, including the sampled fluid around the brain.
- primary_references
- [b6-akitomo2025] Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy (2025). https://pubmed.ncbi.nlm.nih.gov/40387451/ DOI: 10.1002/jimd.70036
- tissue_or_cell_type
- Serum and cerebrospinal fluid
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Vitamin B6: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1657–1667
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Over 100 hypophosphatasia cases, serum vitamers and available CSF; supplementation/enzyme-replacement subgroups. · source_derived_draft · unverified_draft
### b6-hpp-enzyme-replacement-ratio Enzyme replacement was associated with lower serum PLP: PL ratios; CSF PL was higher in treated than untreated cases. Condition category: machinery_impairment nutrient_topic: Vitamin B6 research collection; topical membership is not evidence of a direct dietary effect. plain_language: Restoring enzyme activity changed B6 handling markers, including the sampled fluid around the brain. organism: Homo sapiens tissue_or_cell_type: Serum and cerebrospinal fluid experimental_model: Over 100 hypophosphatasia cases, serum vitamers and available CSF; supplementation/enzyme-replacement subgroups. limitations: Nonrandomized treatment comparisons; does not directly measure transport flux or establish neurological benefit. exposure: Observational clinical sampling by subtype and treatment; no randomized B6 efficacy comparison. [b6-akitomo2025] Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy (2025). https://pubmed.ncbi.nlm.nih.gov/40387451/ DOI: 10.1002/jimd.70036
Complete structured claim and evidenceIn the 2025 cohort, untreated HPP had higher serum PLP and PLP: PL ratios; severe perinatal disease had lower PL than benign perinatal disease and the lowest PA across subtypes.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- experimental_model
- Over 100 hypophosphatasia cases, serum vitamers and available CSF; supplementation/enzyme-replacement subgroups.
- exposure
- Observational clinical sampling by subtype and treatment; no randomized B6 efficacy comparison.
- limitations
- Observational subtype comparison; contextual difference from broader pediatric cohorts, not an editorial conflict.
- nutrient_topic
- Vitamin B6 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin B6
- organism
- Homo sapiens
- plain_language
- Disease severity changes which B6 forms accumulate or become low.
- primary_references
- [b6-akitomo2025] Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy (2025). https://pubmed.ncbi.nlm.nih.gov/40387451/ DOI: 10.1002/jimd.70036
- tissue_or_cell_type
- Human blood and whole-body measurements
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Vitamin B6: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1645–1655
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Over 100 hypophosphatasia cases, serum vitamers and available CSF; supplementation/enzyme-replacement subgroups. · source_derived_draft · unverified_draft
### b6-hpp-severity-vitamer-pattern In the 2025 cohort, untreated HPP had higher serum PLP and PLP: PL ratios; severe perinatal disease had lower PL than benign perinatal disease and the lowest PA across subtypes. Condition category: biomarker_context nutrient_topic: Vitamin B6 research collection; topical membership is not evidence of a direct dietary effect. plain_language: Disease severity changes which B6 forms accumulate or become low. organism: Homo sapiens tissue_or_cell_type: Human blood and whole-body measurements experimental_model: Over 100 hypophosphatasia cases, serum vitamers and available CSF; supplementation/enzyme-replacement subgroups. limitations: Observational subtype comparison; contextual difference from broader pediatric cohorts, not an editorial conflict. exposure: Observational clinical sampling by subtype and treatment; no randomized B6 efficacy comparison. [b6-akitomo2025] Vitamin B6 Status in Hypophosphatasia: Association With Clinical Severity, Diagnostic Utility, and Effects on Vitamin B6 Metabolism by Supplementation and Enzyme Replacement Therapy (2025). https://pubmed.ncbi.nlm.nih.gov/40387451/ DOI: 10.1002/jimd.70036
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.